Journal of Infectious Diseases & Preventive Medicine
Open Access

Characterization of adverse effects and it's associations in the patient medicated with anti-tubercular drugs

Joint Event on Infection Congress 2020 & Tropical Diseases 2020

February 24-25, 2020 | Berlin, Germany

Priyatam Khadka

Tribhuvan University Teaching Hospital, Nepal

Posters & Accepted Abstracts: J Infect Dis Prev Med

Abstract :

Background: Adverse effects from long-term therapeutic intervention in tuberculosis are obvious. However, were taken nonchalantly due to the only therapeutic alternative. Objective: The objective of this study was to characterize the adverse effects and it’s associations in the patient medicated with anti-tubercular drugs. Methods: A longitudinal prospective study was conducted among the patient medicated with anti-tubercular drugs. As per the guideline of Nepal’s National Tuberculosis Control Program me (NTP), Nepal, the treatment category was selected, fixed-dose-regimen was calculated, and treatment outcome was affirmed. Patients’ demographics and other clinical details were extracted from the repository files. Upon a consecutive follow-up, observed adverse effects were noted and multivariate logistic analysis against independent factors was done for elucidating any association. Result: Of 177 cases enrolled, 138(77.9%) reported at least two adverse effects. In our multivariate logistic analysis: female, abnormal Body Mass Index (BMI) i.e. underweight and overweight cases, patients’ behaviors i.e. smoking/ drinking or both clinical diagnosed cases and intensive treatment phase were independently associated with adverse side effects. Loss of appetite (85.4%) was the commonest while dermatologic manifestations (1.2%) and severe weightloss (1.2%) were the least observed side-effects among the patient medicated with anti-tubercular drugs. Absolute drug-induced-toxicity was observed in treatment failure or MDR (Multi-Drug-Resistant) subjects. Conclusion: Adverse effects from anti-tubercular therapy are associated with patients’ demographics variables. Symptomatic treatment, regular follow-up after implicated therapy, and therapeutic-discontinuation may be required for successful outcomes.